Literature DB >> 22956167

Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis.

U Müller-Ladner1, R M Flipo, P Vincendon, Y Brault, D Kielar.   

Abstract

The objective of this study was to investigate patients' perceptions of the acceptability of two devices delivering etanercept for rheumatoid arthritis (RA) treatment and to explore whether specific patients' attributes are associated with device preferences. Two similar multicenter, open-label, randomised, parallel-design studies were conducted in a total of 13 European countries. A total of 640 adult patients with RA were randomised to receive etanercept 50 mg once-weekly subcutaneously for 12 weeks in either a pre-filled syringe (PFS) or a pre-filled pen (PFP). Patient satisfaction at week 12 was measured on a 0- to 10-point Likert scale (primary endpoint). The study was powered to demonstrate non-inferiority of a PFP over PFS for the primary endpoint. At week 12, mean patient satisfaction was 8.3 (± 2.4) points in the pen group and 7.2 (± 2.6) points in the syringe group. Non-inferiority and even superiority of the pen over the syringe was demonstrated. In conclusion, this study showed higher patient satisfaction in the group of patients injecting etanercept with a PFP compared with the group of patients using a PFS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956167     DOI: 10.1007/s00393-012-1034-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  30 in total

1.  Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies.

Authors:  Richard R Rubin; Mark Peyrot
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

2.  Patient preferences in choosing anti-TNF therapies-R1.

Authors:  E L Williams; C J Edwards
Journal:  Rheumatology (Oxford)       Date:  2006-11-03       Impact factor: 7.580

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial.

Authors:  Alan Kivitz; Steven Cohen; James Edward Dowd; William Edwards; Suman Thakker; Frank R Wellborne; Cheryl L Renz; Oscar G Segurado
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

Review 6.  Overview of insulin delivery pen devices.

Authors:  Lisa Kroon
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Sep-Oct

7.  Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.

Authors:  Michael E Weinblatt; Michael H Schiff; Eric M Ruderman; Clifton O Bingham; Juan Li; James Louie; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-07

Review 8.  Emerging therapeutics for rheumatoid arthritis.

Authors:  Clifton O Bingham
Journal:  Bull NYU Hosp Jt Dis       Date:  2008

9.  Patient preferences for treatment of rheumatoid arthritis.

Authors:  L Fraenkel; S T Bogardus; J Concato; D T Felson; D R Wittink
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103

10.  The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.

Authors:  R K Dore; S Mathews; J Schechtman; W Surbeck; D Mandel; A Patel; L Zhou; P Peloso
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473

View more
  3 in total

1.  Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Authors:  Roy M Fleischmann; Amy E Bock; Wuyan Zhang; Charles M Godfrey; Ivana Vranic; Carol Cronenberger; Eva Dokoupilová
Journal:  Rheumatol Ther       Date:  2022-03-18

2.  GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

Authors:  Oliver von Richter; Andrej Skerjanec; Miguel Afonso; Sabine Sanguino Heinrich; Johann Poetzl; Heike Woehling; Maria Velinova; Annelize Koch; Dmitrij Kollins; Lars Macke; Guido Wuerth
Journal:  Br J Clin Pharmacol       Date:  2016-12-16       Impact factor: 4.335

3.  Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.

Authors:  Sang-Hoon Lee; Yong-Gil Kim; Seung-Geun Lee; Soo Hyun Lee; Young-Joo Kim; Ja-Young Jeon; Joo-Young Jo; Hyun-Jeong Yoo; Juneyoung Lee; Tae-Hwan Kim
Journal:  Int J Rheum Dis       Date:  2022-02-20       Impact factor: 2.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.